<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668495</url>
  </required_header>
  <id_info>
    <org_study_id>Cangrelor Timing</org_study_id>
    <nct_id>NCT04668495</nct_id>
  </id_info>
  <brief_title>Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor</brief_title>
  <official_title>Impact of Timing of Pharmacodynamic Assessments on Measures of Platelet Reactivity in Patients Undergoing Percutaneous Coronary Intervention Treated With Cangrelor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is assessing the impact of timing of PD assessments on measures of platelet&#xD;
      reactivity in patients undergoing PCI treated with cangrelor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cangrelor is characterized by reversible binding to the P2Y12 receptor and is promptly&#xD;
      inactivated through dephosphorylation by ectonucleotidase leading to its very short plasma&#xD;
      half-life. Consequently the timing at which PD assessments are performed after blood sample&#xD;
      collection may impact measures of platelet reactivity in patients treated with cangrelor. We&#xD;
      therefore hypothesize that measures of platelet inhibitory effects observed in cangrelor&#xD;
      treated patients will reduce with time following blood sampling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Actual">July 20, 2021</completion_date>
  <primary_completion_date type="Actual">April 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in platelet reactivity</measure>
    <time_frame>wiithin 30 min, 1 hour, 2 hours, and 4 hours of blood sampling</time_frame>
    <description>measure of change platelet reactivity at time points</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">17</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cangrelor Group</arm_group_label>
    <description>This is the study cohort that the blood sample will be obtained from. There are no interventions</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are undergoing percutaneous coronary intervention (PCI) and have been treated&#xD;
        with cangrelor per standard of care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  CAD patients (stable CAD, NSTE-ACS, or STEMI) undergoing PCI and treated with&#xD;
             cangrelor per standard of care.&#xD;
&#xD;
          -  Treated with aspirin prior to the PCI procedure per standard of care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with an oral P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) within&#xD;
             past 10 days&#xD;
&#xD;
          -  Treatment with oral anticoagulation (vitamin K antagonist, dabigatran, apixaban,&#xD;
             rivaroxiban) within past 3 days&#xD;
&#xD;
          -  Treatment with a glycoprotein IIb/IIIa inhibitor during PCI&#xD;
&#xD;
          -  Fibrinolytics within 48 hours&#xD;
&#xD;
          -  Known hemoglobin&lt;10 gm/dL&#xD;
&#xD;
          -  Known platelet count &lt;80x106/mL&#xD;
&#xD;
          -  Active bleeding or hemodynamic instability&#xD;
&#xD;
          -  Known end stage renal disease on hemodialysis&#xD;
&#xD;
          -  Known severe hepatic dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dominick Angiolillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

